GlassScriptPhysician profile
Thomas S Johnston
NPI 1023103462
$1,976.13
in general payments reported to CMS, 2019-2025
22 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $61.06 · 2021: $135 · 2022: $374 · 2023: $678 · 2024: $186 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $734.15 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Pfizer INC. | $421.82 | 2019-2025 | |
| Edwards Lifesciences Corporation | $168.34 | 2022 | |
| Getinge USA Sales, LLC | $91.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.01 | 2022-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $64.14 | 2019-2024 | Xarelto |
| Amgen INC. | $63.51 | 2019-2021 | |
| Boston Scientific Corporation | $63.29 | 2022-2025 | Farapulse |
| Novartis Pharmaceuticals Corporation | $51.23 | 2019-2025 | |
| Novo Nordisk INC | $47.00 | 2023 | Wegovy |
| Atricure, INC. | $22.63 | 2023 | |
| Philips North America LLC | $22.01 | 2025 | Ecc Solutions |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.00 | 2019-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.97 | 2020 | |
| Alnylam Pharmaceuticals INC. | $18.14 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $17.97 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $15.96 | 2024 | Wainua |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.92 | 2019 | |
| Astellas Pharma US INC | $13.17 | 2021 | |
| Amarin Pharma, INC. | $12.43 | 2021 | |
| Altathera Pharmaceuticals LLC | $9.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Johnston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.